SodiumChloride
PreclinicalSmall molecule
SodiumChloride is one of 31 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
26 competitors in Hypoglycemia
#DrugCompanyPhaseTrials
1Aldactone
PfizerApproved
NOVOLIN R
Novo NordiskApproved
Avelox
BayerApproved
Narcan
SScienture
Approved
Symlin
AstraZenecaApproved
Proglycem
TevaApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Luxiq
SSchering-Plough
Approved
Reglan
IIstituto Clinico Humanitas
Phase 2
Avexitide
AAmylyx Pharmaceuticals Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SodiumChloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details